[Therapy of prostate carcinoma with polyamine synthesis inhibitors. I. Physiological and pathophysiological principles].
The therapeutic concept of irreversible inhibition of both ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (SAMDC) by alpha-difluoromethylornithine (DFMO) and methylglyoxal bis-guanylhydrazone (MGBG) is based on pathologic activities of these enzymes in tumor tissue. The polyamines putrescine, spermidine and spermine are measured in highest concentration in the prostate of both men and animals, with a significant increase of spermine in benign hyperplasia of the prostate. Patients with metastatic cancer of the prostate have elevated putrescine levels in the 24-hour urine. Treatment with 3 or 1% DFMO or 11 mg/kg MGBG in transplantable human and experimental cancer of the prostate demonstrated a significant anti-growth effect. A combination of DFMO and MGBG is tumor-destructive. The combination of 1% DFMO and 11 mg/kg MGBG distinctly reduces the activity of ODC and SAMDC and significantly lowers the levels of putrescine, spermidine and spermine in the tumor.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011073:Polyamines / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011700:Putrescine / Q000627:therapeutic use; D013095:Spermidine / Q000627:therapeutic use; D013096:Spermine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011073:Polyamines; D013096:Spermine; D013095:Spermidine; D011700:Putrescine
Therapie des Prostatakarzinoms mit Polyaminsyntheseinhibitoren. I. Physiologische und pathophysiologische Grundlagen.